Purpose To review the impact of tyrosine kinase inhibitors (TKIs) on fertility in men and
women, embryo development, and early pregnancy, and discuss considerations for fertility …

Abstract Purpose Tyrosine kinase inhibitors (TKIs) such as imatinib are commonly used
chemotherapeutics, but the effects of long-term treatments on reproductive outlook for …

The aim of the study was to evaluate ovarian toxicity of tyrosine kinase inhibitor (TKI)
sunitinib, since only scarce data are available on gonadal function after this treatment. Six …

Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents
used widely to treat Philadelphia‐positive leukemias and selected other cancers, leading to …

Objective: To review the safety issues surrounding tyrosine kinase inhibitors (TKIs),
specifically, hematological adverse effects, cardiovascular issues, renal adverse effects and …

The introduction of tyrosine kinase inhibitors into clinical practice now offers most patients
with chronic myelogenous leukemia lengthy remissions and the possibility of normal life …

Background The aim of this work was to report on the outcome of pregnancy in patients with
chronic myeloid leukaemia who were on tyrosine kinase inhibitor treatment. Patients and …

Imatinib is an oral chemotherapeutic used primarily to treat chronic myeloid leukemia (CML)
and gastrointestinal stromal tumors (GIST). The potential effects of cancer treatments on a …

Imatinib should be avoided in women planning to become pregnant or during pregnancy,
due to a higher risk of congenital malformations. However, it is not known whether imatinib …

The success of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid
leukaemia (CML) has resulted in a return to a normal life expectancy for the majority of …